Pramipexole 2HCl Monohydrate

Research use only, not for human use.

Pramipexole Dihydrochloride is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Pramipexole Dihydrochloride is a D2/3 agonist. It acts by reducing mitochondrial ROS production and inhibiting the activation of apoptotic pathways.(In Vitro):Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.(In Vivo):Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole dihydrochloride hydrate improves neurological recovery.Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke.

Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole dihydrochloride hydrate (0.01-10?μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.

Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole dihydrochloride hydrate improves neurological recovery.Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Animal Model:Male Wistar rats weighing 250-300 g (16-18 weeks old)Dosage:0.25 mg/kg, 1 mg/kg Administration:Intraperitoneal injection Result:Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.

Pramipexole Dihydrochloride Monohydrate | Pramipexole Dihydrochloride

Others

Other Targets

D2S|D2L|D3|D4

Neurological Disease

——

191217-81-9

302.26

C10H17N3S·2HCl·H2O

>98% (HPLC)

In Vitro:?H2O : 100 mg/mL (330.84 mM)

O.Cl.CCCN[C@H]1CCc2c(C1)sc(N)n2.Cl

(S)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride hydrate

(-20℃)

With Ice Pack

≥ 2 years